jim cramer eli lilly glp-1 says popularity weight loss drugs new investing opportunities Why Eli Lilly will win

The consumers who use GLP-1s may be more willing to try new products, they added, and those CPG items marketed as high protein, high fiber, nutrient added and GLP-1 friendly are currently selling well

Whether hyperglycaemia itself directly affects the pathogenesis of atherosclerosis and heart failure remains inconclusive

The preclinical data suggests the hypothesis that inhibitory GIPR + neurons act specifically on GLP-1R + neurons that drive nausea and food aversion or avoidance to dampen GLP-1R mediated nausea without reducing efficacy, potentially lifting the ceiling of GLP-1R agonist-induced reductions in body weight

Concerns the FDA has flagged for this category generally - not specific to VivioMD - include: Dosing errors and confusion between milliliters, milligrams, and units in compounded injectable semaglutide Products sold as "semaglutide" that may actually contain salt forms such as semaglutide sodium or semaglutide acetate, which differ from the FDA-approved active ingredient and haven't been evaluated for safety or effectiveness Improper storage and shipping conditions for compounded injectables Fraudulent labels and doses beyond approved-label schedules Underreported adverse events across the compounded-GLP-1 category The FDA recommends that compounded drugs be used only for patients whose medical needs cannot be met by an FDA-approved drug - not as a default lower-cost substitute

50,51 GIP infusion reduced aortic plaque formation, intra-plaque macrophage accumulation, and foam cell formation in diabetic mice, while its overexpression stabilizes the atherosclerotic plaque in non-diabetic animals